160 related articles for article (PubMed ID: 36271964)
1. Development of a cost-effective diagnostic algorithm incorporating transcription factor immunohistochemistry in the evaluation of pituitary tumours.
Lenders NF; Chui J; Low J; Inder WJ; Earls PE; McCormack AI
Pituitary; 2022 Dec; 25(6):997-1003. PubMed ID: 36271964
[TBL] [Abstract][Full Text] [Related]
2. Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors.
Silva-Ortega S; García-Martinez A; Niveiro de Jaime M; Torregrosa ME; Abarca J; Monjas I; Picó Alfonso A; Aranda López I
Hum Pathol; 2021 Apr; 110():20-30. PubMed ID: 33321163
[TBL] [Abstract][Full Text] [Related]
3. Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification.
Dottermusch M; Schüller U; Hagel C; Saeger W
Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12870. PubMed ID: 36527335
[TBL] [Abstract][Full Text] [Related]
4. Transcription factor immunohistochemistry in the diagnosis of pituitary tumours.
Lenders NF; Wilkinson AC; Wong SJ; Shein TT; Harvey RJ; Inder WJ; Earls PE; McCormack AI
Eur J Endocrinol; 2021 May; 184(6):891-901. PubMed ID: 33852418
[TBL] [Abstract][Full Text] [Related]
5. The Role of T-box Transcription Factor in a Pituitary Adenoma Diagnostic Algorithm.
McDonald WC; McDonald KN; Helmer JA; Ho B; Wang A; Banerji N
Arch Pathol Lab Med; 2021 May; 145(5):592-598. PubMed ID: 32991684
[TBL] [Abstract][Full Text] [Related]
6. Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A Rational Starting Place for the Immunohistochemical Characterization of Pituitary Adenoma.
McDonald WC; Banerji N; McDonald KN; Ho B; Macias V; Kajdacsy-Balla A
Arch Pathol Lab Med; 2017 Jan; 141(1):104-112. PubMed ID: 27227698
[TBL] [Abstract][Full Text] [Related]
7. Plurihormonal Pituitary Neuroendocrine Tumours - A Single Centre Experience.
Mihajlović M; Pekić S; Doknić M; Stojanović M; Rašić D; Miljić D; Petakov M; Manojlović Gačić E
Int J Surg Pathol; 2024 May; 32(3):470-477. PubMed ID: 37438981
[No Abstract] [Full Text] [Related]
8. Pituitary tumours without distinct lineage differentiation express stem cell marker SOX2.
Lenders NF; Thompson TJ; Chui J; Low J; Inder WJ; Earls PE; McCormack AI
Pituitary; 2024 Jun; 27(3):248-258. PubMed ID: 38483762
[TBL] [Abstract][Full Text] [Related]
9. Transcription Factor Immunohistochemistry in the Classification of Pituitary Neuroendocrine Tumor/Adenoma: Proposal in a Limited-Resource Setting.
Sood R; Chatterjee D; Dutta P; Radotra BD
Arch Pathol Lab Med; 2024 Feb; 148(2):178-189. PubMed ID: 37074863
[TBL] [Abstract][Full Text] [Related]
10. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor expression and clinical outcome of multilineage pituitary tumours expressing PIT1 and SF1.
Fookeerah P; Varikatt W; Shingde M; Dexter MAJ; McLean M
Endocr Connect; 2023 Nov; 12(11):. PubMed ID: 37851558
[TBL] [Abstract][Full Text] [Related]
12. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
[TBL] [Abstract][Full Text] [Related]
13. [Plurihormonal PIT1-lineage pituitary neuroendocrine tumors: a clinicopathological study].
Duan ZJ; Feng J; Zhao HQ; Wang HD; Gui QP; Zhang XF; Ma Z; Hu ZJ; Xiang L; Qi XL
Zhonghua Bing Li Xue Za Zhi; 2023 Oct; 52(10):1017-1024. PubMed ID: 37805393
[No Abstract] [Full Text] [Related]
14. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
[TBL] [Abstract][Full Text] [Related]
15. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors.
Mete O; Asa SL
Endocr Pathol; 2020 Dec; 31(4):330-336. PubMed ID: 32813227
[TBL] [Abstract][Full Text] [Related]
16. Utility of GATA-3 Expression in the Analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors.
Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
Endocr Pathol; 2020 Jun; 31(2):150-155. PubMed ID: 32193825
[TBL] [Abstract][Full Text] [Related]
17. Pituitary adenomas with multiple cell lineage combinations: clinicopathological features and short-term prognosis.
Tang H; Wang X; Bie Z; Yang Z; Wang B; Li S; Liu P
J Neurosurg; 2023 Sep; 139(3):810-821. PubMed ID: 36708537
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology.
Doğukan FM; Karatay H; Yüzkan S; Burhan Ş; Erkan B; Yılmaz-Özgüven B
Arch Pathol Lab Med; 2024 Apr; ():. PubMed ID: 38649148
[TBL] [Abstract][Full Text] [Related]
19. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version].
Xie J; Wu ZB
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420
[TBL] [Abstract][Full Text] [Related]
20. Reverse transcription polymerase chain reaction analysis of pituitary hormone, Pit-1 and steroidogenic factor-1 messenger RNA expression in pituitary tumors.
McDermott MT; Haugen BR; Gordon DF; Wood WM; Brown NS; Bauer CA; Garrity MJ; Kleinschmidt-DeMasters BK; Lillehei KO; Samuels MH; Bright TM; Ridgway EC
Pituitary; 1999 Nov; 2(3):217-24. PubMed ID: 11081157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
